We investigated risk factors for the development of mixed chimerism in 131 patients who
underwent transplantation for myelofibrosis and determined the impact of lymphoid (CD3+) …

The aim of this retrospective study was to assess the rate of full donor chimerism (F‐DC) in
patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two …

Allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative
treatment for myelofibrosis (MF). 1, 2 The 5-year overall survival (OS) rates in MF patients …

A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age
of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) …

We aim to evaluate impact of donor types on outcomes of hematopoietic cell transplantation
(HCT) in myelofibrosis, using CIBMTR registry data for HCTs done between 2013 and 2019 …

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the sole curative option for
myelofibrosis (MF). Relapse remains a significant problem, however, occurring in up to 20 …

We report the results from a multicenter retrospective study of 69 adult patients who
underwent haploidentical blood or marrow transplantation (haplo-BMT) with post …

Myelofibrosis (MF) is a chronic progressive hematologic malignancy with a median overall
survival (OS) of approximately 6 years. Allogeneic hematopoietic stem cell transplantation …

This is a retrospective analysis of 95 patients with myelofibrosis who were allografted
between 2001 and 2014. The aims of the study were to assess whether the outcome of …

In this cross-sectional study, we retrospectively evaluated the files of 227 patients with
myelofibrosis who underwent transplantation between 1994 and 2015 for relapse later than …